PL3055321T3 - SYNTETAZY tRNA DOŁĄCZAJĄCE AMINOKWAS NIENATURALNY DLA PARA-METYLOAZYDO-L-FENYLOALANINY - Google Patents
SYNTETAZY tRNA DOŁĄCZAJĄCE AMINOKWAS NIENATURALNY DLA PARA-METYLOAZYDO-L-FENYLOALANINYInfo
- Publication number
- PL3055321T3 PL3055321T3 PL14852519T PL14852519T PL3055321T3 PL 3055321 T3 PL3055321 T3 PL 3055321T3 PL 14852519 T PL14852519 T PL 14852519T PL 14852519 T PL14852519 T PL 14852519T PL 3055321 T3 PL3055321 T3 PL 3055321T3
- Authority
- PL
- Poland
- Prior art keywords
- methylazido
- phenylalanine
- para
- amino acid
- natural amino
- Prior art date
Links
- 102000003960 Ligases Human genes 0.000 title 1
- 108090000364 Ligases Proteins 0.000 title 1
- 229940024606 amino acid Drugs 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 title 1
- 229960005190 phenylalanine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
- C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
- C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C12Y601/01001—Tyrosine-tRNA ligase (6.1.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361890028P | 2013-10-11 | 2013-10-11 | |
| PCT/US2014/060058 WO2015054587A1 (en) | 2013-10-11 | 2014-10-10 | NON-NATURAL AMINO ACID tRNA SYNTHETASES FOR PARA-METHYLAZIDO-L-PHENYLALANINE |
| EP14852519.9A EP3055321B1 (en) | 2013-10-11 | 2014-10-10 | NON-NATURAL AMINO ACID tRNA SYNTHETASES FOR PARA-METHYLAZIDO-L-PHENYLALANINE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3055321T3 true PL3055321T3 (pl) | 2019-02-28 |
Family
ID=52813666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14852519T PL3055321T3 (pl) | 2013-10-11 | 2014-10-10 | SYNTETAZY tRNA DOŁĄCZAJĄCE AMINOKWAS NIENATURALNY DLA PARA-METYLOAZYDO-L-FENYLOALANINY |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9938516B2 (pl) |
| EP (1) | EP3055321B1 (pl) |
| DK (1) | DK3055321T3 (pl) |
| ES (1) | ES2697778T3 (pl) |
| HU (1) | HUE042421T2 (pl) |
| PL (1) | PL3055321T3 (pl) |
| WO (1) | WO2015054587A1 (pl) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9951392B2 (en) * | 2014-03-14 | 2018-04-24 | Northwestern University | Substrate replenishment and byproduct removal improve yeast cell-free protein synthesis |
| US10316322B2 (en) * | 2014-07-02 | 2019-06-11 | Sutro Biopharma, Inc. | High growth capacity auxotrophic Escherichia coli and methods of use |
| US10118950B2 (en) * | 2014-08-30 | 2018-11-06 | Northwestern University | Platforms for cell-free protein synthesis comprising extracts from genomically recoded E. coli strains having genetic knock-out mutations in release factor 1 (RF-1) and endA |
| US10465221B2 (en) * | 2016-07-15 | 2019-11-05 | Northwestern University | Genomically recoded organisms lacking release factor 1 (RF1) and engineered to express a heterologous RNA polymerase |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| CN110366428B (zh) * | 2016-12-30 | 2024-05-17 | Vaxcyte公司 | 具有非天然氨基酸的多肽-抗原缀合物 |
| KR20250171416A (ko) | 2017-07-11 | 2025-12-08 | 신톡스, 인크. | 비천연 뉴클레오티드의 도입 및 그의 방법 |
| BR112020002272A2 (pt) | 2017-08-03 | 2020-07-28 | Synthorx, Inc. | conjugados de citocina para o tratamento de doenças autoimunes |
| CN112105627B (zh) | 2017-12-29 | 2024-07-02 | 斯克利普斯研究所 | 非天然碱基对组合物及使用方法 |
| TWI834636B (zh) | 2018-02-26 | 2024-03-11 | 美商欣爍克斯公司 | Il-15結合物及其用途 |
| WO2020010016A1 (en) * | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
| CN112543649A (zh) * | 2018-07-04 | 2021-03-23 | Vaxcyte公司 | 免疫原性缀合物的改进 |
| WO2020010000A1 (en) * | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
| TW202031284A (zh) | 2018-11-08 | 2020-09-01 | 美商新索思股份有限公司 | 介白素10結合物及其用途 |
| US20200246467A1 (en) | 2019-02-06 | 2020-08-06 | Synthorx, Inc. | Il-2 conjugates and methods of use thereof |
| MX2021012120A (es) * | 2019-04-02 | 2021-11-03 | Vaxcyte Inc | Sintesis optimizada libre de celulas del antigeno b del plasmido de invasion y composiciones y metodos de uso relacionados. |
| JP7728181B2 (ja) | 2019-06-14 | 2025-08-22 | ザ スクリプス リサーチ インスティテュート | 半合成生物における複製、転写および翻訳のための試薬ならびに方法 |
| CA3150163A1 (en) | 2019-08-15 | 2021-02-18 | Synthorx, Inc. | Immuno oncology combination therapies with il-2 conjugates |
| BR112022003046A8 (pt) | 2019-08-23 | 2024-02-06 | Synthorx Inc | Conjugado de il-15, seu método de preparo e seus usos, bem como composição farmacêutica e método in vitro de expansão de uma ou mais das populações de células t |
| EP4028060A1 (en) | 2019-09-10 | 2022-07-20 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| CA3156405A1 (en) | 2019-11-04 | 2021-05-14 | Synthorx, Inc. | Interleukin 10 conjugates and uses thereof |
| EP4107258A4 (en) * | 2020-02-20 | 2024-04-17 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | MUTANT AMINOACYL-ARNT SYNTHETASES |
| US12351850B2 (en) | 2020-04-30 | 2025-07-08 | Sutro Biopharma, Inc. | Methods of producing full-length antibodies using E. coli |
| BR112022026236A2 (pt) | 2020-06-25 | 2023-01-17 | Synthorx Inc | Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr |
| WO2022076859A1 (en) | 2020-10-09 | 2022-04-14 | Synthorx, Inc. | Immuno oncology therapies with il-2 conjugates |
| AU2021356693A1 (en) | 2020-10-09 | 2023-06-15 | Synthorx, Inc. | Immuno oncology combination therapy with il-2 conjugates and pembrolizumab |
| WO2022174102A1 (en) | 2021-02-12 | 2022-08-18 | Synthorx, Inc. | Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof |
| TW202245843A (zh) | 2021-02-12 | 2022-12-01 | 美商欣爍克斯公司 | Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法 |
| KR102496720B1 (ko) * | 2021-03-04 | 2023-02-06 | 전남대학교 산학협력단 | 티로실-tRNA 합성효소 돌연변이체 및 이를 이용한 단백질 생산방법 |
| WO2022256538A1 (en) | 2021-06-03 | 2022-12-08 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab |
| KR102772739B1 (ko) * | 2021-11-08 | 2025-02-26 | 전남대학교 산학협력단 | 재조합 티로실-tRNA 합성효소 및 이를 이용한 단백질 생산 방법 |
| EP4452327A1 (en) | 2021-12-20 | 2024-10-30 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
| WO2023122750A1 (en) | 2021-12-23 | 2023-06-29 | Synthorx, Inc. | Cancer combination therapy with il-2 conjugates and cetuximab |
| WO2024136899A1 (en) | 2022-12-21 | 2024-06-27 | Synthorx, Inc. | Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies |
| EP4683671A1 (en) | 2023-03-20 | 2026-01-28 | Synthorx, Inc. | Cancer therapy with il-2 peg conjugates |
| EP4689127A1 (en) | 2023-04-03 | 2026-02-11 | Sutro Biopharma, Inc. | Rf1 ko e. coli strains |
| CN117658866B (zh) * | 2023-12-07 | 2026-02-03 | 苏州爱玛特生物科技有限公司 | 一种叠氮氨基酸衍生物的合成方法 |
| WO2025158385A1 (en) | 2024-01-25 | 2025-07-31 | Genzyme Corporation | Pegylated il-2 for suppressing adaptive immune response to gene therapy |
| WO2025207517A2 (en) | 2024-03-25 | 2025-10-02 | Synthorx, Inc. | Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8216804B2 (en) * | 2004-10-27 | 2012-07-10 | The Scripps Research Institute | Orthogonal translation components for the in vivo incorporation of unnatural amino acids |
-
2014
- 2014-10-10 EP EP14852519.9A patent/EP3055321B1/en active Active
- 2014-10-10 WO PCT/US2014/060058 patent/WO2015054587A1/en not_active Ceased
- 2014-10-10 DK DK14852519.9T patent/DK3055321T3/en active
- 2014-10-10 US US15/028,396 patent/US9938516B2/en active Active
- 2014-10-10 ES ES14852519T patent/ES2697778T3/es active Active
- 2014-10-10 PL PL14852519T patent/PL3055321T3/pl unknown
- 2014-10-10 HU HUE14852519A patent/HUE042421T2/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2697778T3 (es) | 2019-01-28 |
| EP3055321A1 (en) | 2016-08-17 |
| EP3055321B1 (en) | 2018-10-10 |
| US9938516B2 (en) | 2018-04-10 |
| WO2015054587A1 (en) | 2015-04-16 |
| EP3055321A4 (en) | 2017-03-22 |
| DK3055321T3 (en) | 2018-12-17 |
| US20160257946A1 (en) | 2016-09-08 |
| HUE042421T2 (hu) | 2019-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3055321T3 (pl) | SYNTETAZY tRNA DOŁĄCZAJĄCE AMINOKWAS NIENATURALNY DLA PARA-METYLOAZYDO-L-FENYLOALANINY | |
| EP3055320A4 (en) | NON-NATURAL AMINO ACID tRNA SYNTHETASES FOR PYRIDYL TETRAZINE | |
| SG11201600473UA (en) | Amino acid derivatives | |
| SI3011037T1 (sl) | Gen, odporen proti rizomaniji | |
| EP2859242A4 (en) | EJECTORS | |
| EP2954725A4 (en) | IMPROVED HANDOVER SOLUTION | |
| DK2800476T3 (da) | Fremgangsmåde til fodring | |
| PL2943561T3 (pl) | Fotobioreaktor | |
| GB201315777D0 (en) | Novel method | |
| GB201308313D0 (en) | Assay Method | |
| GB201403402D0 (en) | Accurate halver | |
| SG11201509988RA (en) | Transaminase biocatalysts | |
| SG10201802023RA (en) | Protein production method | |
| GB201310151D0 (en) | Novel method | |
| GB201303906D0 (en) | Assay method | |
| GB201415000D0 (en) | Improved process | |
| SG10201401381SA (en) | Acid injection | |
| PT2771485T (pt) | Processo para identificar aptâmeros | |
| PL2886651T3 (pl) | Sposób wytwarzania l-aminokwasu | |
| ZA201506235B (en) | Seated end process | |
| GB201315532D0 (en) | Methods for detecting proteins | |
| EP2810933A4 (en) | PROCESS FOR PREPARING A SOLID AMINO ACID | |
| GB201306308D0 (en) | Novel process | |
| IL244700A0 (en) | Process for preparing gabapentin | |
| SG2013095815A (en) | Mirror-monitor (variants) |